Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures

NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) today announced top-line results for a Phase 3 study that showed Lyrica® (pregabalin) Capsules CV were as effective as levetiracetam as an adjunctive therapy in adult epilepsy patients... Biopharmaceuticals, NeurologyPfizer, Lyrica, pregabalin, levetiracetam, epilepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news